DBV Technologies S.A. Announces Proposed Global Offering

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DBV Technologies S.A. Announces Proposed Global Offering

BAGNEUX, France, Oct. 20, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), a clinical-stage specialty biopharmaceutical company announced today that it intends to offer and sell, subject to market and other conditions, up to 2,673,641 of its ordinary shares in a global offering, which is comprised of an offer of ordinary shares in the form of American Depositary Shares, or ADSs, in the United States, Canada and countries outside of France in an underwritten public offering through U.S. underwriters and an offer of ordinary shares in France and countries outside of the United States and Canada in a concurrent registered private placement through international underwriters. DBV intends to grant the U.S. underwriters a 30-day option to purchase additional ordinary shares in the form of ADSs in connection with the U.S. offering and the international underwriters a 30-day option to purchase up to additional ordinary shares in connection with the international registered private placement, up to a maximum of 3,074,686 ordinary shares to be sold in the global offering. The closing of the U.S. offering and the international registered private placement will be conditioned on each other.

Each of the ADSs offered in the U.S. offering represents the right to receive one-half of one ordinary share. Application has been made for listing of the ADSs on the Nasdaq Global Select Market under the symbol "DBVT."

The ordinary shares are listed on Euronext Paris under the symbol "DBV."

The settlement of the global offering and the admission of the new shares on the Nasdaq Global Select Market and Euronext Paris are expected to occur on 24 October 2014.

Citigroup Global Markets Inc., Leerink Partners LLC and Bryan, Garnier & Co. are acting as joint global coordinators and joint book-running managers of the global offering. Citigroup Global Markets Inc. and Leerink Partners LLC are acting as representatives of the U.S. underwriters. Citigroup Global Markets Limited is acting as representative of the international underwriters. The U.S. underwriters are Citigroup Global Markets Inc, Leerink Partners LLC, Bryan, Garnier & Co and Trout Capital LLC.  The international underwriters are Citigroup Global Markets Limited and Bryan, Garnier & Co.

The offering of ADS will be made only by the means of a prospectus. When available, copies of the prospectus relating to the offering of ADS may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 1-800-831-9146; email: prospectus@citi.com; Leerink Partners LLC,  Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: 1-800-808-7525 ext. 6142; email: Syndicate@Leerink.com; and Bryan, Garnier & Co., Attention: Prospectus Department, 26 Avenue des Champs-Élysées, 75008 Paris France, telephone: +33 1 56 68 75 20; email: prospectus@bryangarnier.com.

A registration statement relating to the ADS has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The ADS may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the ADS in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the Reference Document registered by the AMF on April 16th, 2014 under No. 14-017 and its update filed with the AMF on September 22nd, 2014 under No. D.14-0286-A01 are available free of charge at DBV Technologies' head office in Green Square, 80/84 rue des Meuniers - 92220 Bagneux - France, and on the website of the AMF ( www.amf-france.org ). A securities note ( note d'opération ) related to the admission to trading of the new shares on Euronext Paris will be submitted for visa to the AMF and will be published on the website of the AMF ( www.amf-france.org ).

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure.

DBV Technologies ordinary shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

Forward Looking Statements

This press release contains forward-looking statements, including statements about the proposed timing and size of the global offering and the allocation of shares across these offerings.  These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results.  A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers .  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies Contacts

David Schilansky
Chief Financial Officer
Tel. : +33(0)1 55 42 78 78
david.schilansky@dbv-technologies.com

 
 
Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tel. : +1 917-346-3447
susanna.mesa@dbv-technologies.com
Nathalie Donne
Director, Corporate Communication & Business Development
Tel. : +33(0)1 55 42 78 78
nathalie.donne@dbv-technologies.com
 
DBV IR and Media Contacts
 
 
The Trout Group
U.S. Investor Relations
Todd James
Tel. : +1 646-378-2926
tjames@troutgroup.com
Rooney & Associates
Media Relations
Marion Janic
Tel. : +1-212-223-4017
mjanic@rooneyco.com

DBV Technologies S.A. Announces Proposed Global Offering http://hugin.info/156437/R/1864291/654301.pdf

HUG#1864291

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 110

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 36

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 12

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 72

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 68

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 148

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Cooling Garment Enhances Comfort and Safety

Updated Category News Views 195

Innovative Cooling Garment Enhances Comfort and Safety An inventive idea emerges from Pittsburgh, where a passionate creator from Yonkers has designed a unique garment to provide comfort during hot weather. This innovative attire, aptly named the GAIT, offers a cooling effect that surrounds wearers, ensuring they stay safe and comfortable no matter the temperature. The...

Continue Reading
Discovering Next-Gen Oncology Treatments at the ASH Meeting

Updated Category News Views 229

Innovative Presentations from Nurix Therapeutics NURIX Therapeutics, Inc. (NASDAQ: NRIX), a pioneering biopharmaceutical company dedicated to transforming cancer treatment, is set to showcase its significant advancements at a renowned medical meeting. Updated clinical data from the NX-5948-301 Phase 1a/1b trial has been selected for presentation at the 67th American...

Continue Reading
OU Health Partners with Razom to Transform Surgical Training

Updated Category News Views 264

OU Health and Razom Enhance Humanitarian Surgical Training In an inspiring collaboration, OU Health has recently welcomed a significant cohort of Ukrainian surgeons into its humanitarian training program, marking an important milestone in providing essential surgical training for those addressing complex trauma injuries. Expanding the Program The program, which has just...

Continue Reading
Investors Urged to Act: Lead the Charge Against Sarepta

Updated Category News Views 150

Investors May Have A Path Forward Against Sarepta Therapeutics For those who invested in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and have faced significant losses, recent developments present an opportunity to take action. There exists a growing concern regarding the safety implications of one of the company’s leading products, raising questions about transparency and...

Continue Reading
Lindian's Bold Leap into Rare Earths Processing

Updated Category News Views 58

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Continue Reading